WBI Welichem Biotech Inc.

VANCOUVER, Feb. 2 /CNW/ -- VANCOUVER, Feb. 2 /CNW/ - Welichem Biotech is pleased to announce the successful completion of two Phase II clinical trials with WBI-1001 on psoriasis and atopic dermatitis. Both studies were 12-week, double-blinded, placebo-controlled clinical trials conducted under the regulatory guidelines of Health Canada. Based on analysis of the data, both the primary and secondary efficacy and safety endpoints were met in both studies. ON BEHALF OF THE BOARD Dr. John M. Webster, Chairman of the Board About Welichem Biotech Inc. Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune disease and cancer. To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2011/02/c7375.html pLiren Tang, PhD.br/ Chief Executive Officer.br/ Tel.: (604) 432-1703, E-mail: a href="mailto:lirentang@welichem.com"lirentang@welichem.com/a/p

Copyright